Up to 1 in 3 patients may not be responding adequately to their antiplatelet medications such as aspirin or Plavix®.1

Numerous factors may contribute to inadequate response, including2 :

  • Drug interactions (e.g. Proton Pump Inhibitors)
  • Genetic polymorphisms (e.g. CYP2C19)
  • Pre-existing health conditions (e.g. Diabetes)
  • Non-compliance

And, patients who are not responding adequately to their antiplatelet medications may be at 5 to 10 times greater risk for heart attack, stent thrombosis or death.2-5

Physicians routinely test their patient’s cholesterol level, PT/INR, and blood pressure to verify whether their commonly prescribed medications, such as Lipitor®, Coumadin® and NORVASC®, are producing the desired effect. The VerifyNow® System can help assess your patients’ response to antiplatelet medications such as aspirin and Plavix, two of the most commonly used and prescribed medications.6-8


In-Office Testing Is Now Available and Easy

The VerifyNow System provides you with an easy, rapid and proven solution to help assess your patient's response to antiplatelet medications such as aspirin ,Plavix and Effient.

  • One Easy Procedure
    Whole blood, closed-tube sampling. No pipetting or sample preparation required.
  • Result in Minutes *
    Obtain patient information while they are in your office.
  • CLIA-Waived
    The VerifyNow Aspirin Test is CLIA-waived.
  • Reimbursable
    Tests are reimbursable through CPT codes.

* additional sample incubation required, varies by test

The Benefits of Testing
  • Determine Response
    Identify poor responders who may be at increased risk of heart attack, stent thrombosis and death.
  • Improve Patient Care
    Ensure your patient is receiving maximum benefits of their life-saving medications.
  • Assess Patient Compliance
    Verify your patients are actually taking their medications such as aspirin ,Plavix and Effient.

The VerifyNow System helps you assess your patient’s response to the following antiplatelet medications:

Click here to learn why you should join the growing number of physicians who utilize the VerifyNow System in their office.

  • Dupont, AG. et al. Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome. Thromb Res. 2009 May;124(1):6-13.
  • Patti, G. et al. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention. Results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol. 2008; 52:1128–33.
  • Marcucci, R. et al. Cardiovascular death and nonfatal myocardial Infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay. A 12-Month follow-Up. Circulation. 2009;119(2):237-42.
  • Cuissett, T. et al. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am J CardioI;2008 Jun 15;101(12):1700-3.
  • Price, MJ. et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008 Apr;29(8):992-1000